Spyre Therapeutics Director Jeffrey Albers Resigns from Board
Spyre Therapeutics disclosed the resignation of director Jeffrey Albers effective May 27, 2026. The move triggers standard SEC reporting obligations and leaves the board with one fewer independent director until a replacement is named.
insidermonkey.comSpyre Therapeutics, Inc. reported that director Jeffrey Albers resigned from its board of directors effective May 27, 2026, according to an 8-K filed with the SEC on May 29, 2026.
The filing lists the resignation under Item 5.02 and states that Albers did not cite any disagreement with the company on any matter relating to its operations, policies or practices. Spyre Therapeutics did not disclose a successor in the filing.
The company also reported results from its annual meeting of stockholders under Item 5.07. Specific vote tallies on director elections, auditor ratification or other proposals were not detailed in the summary data of the filing.
Albers' departure changes the board composition from its prior state. Public companies must maintain audit, compensation and nominating committees that satisfy Nasdaq or NYSE independence and expertise rules; the loss of one independent director requires the board to assess compliance and either fill the vacancy or operate with a smaller board until a replacement is appointed.
Spyre Therapeutics must update its disclosures in its next proxy statement or Form 10-K to reflect the change in board membership.
Downstream, the company is required to file any subsequent Form 8-K if a new director is elected and to ensure continued compliance with SEC and exchange listing standards on board independence. Failure to maintain proper board composition could affect the company's ability to file registration statements on Form S-3 or trigger shareholder litigation risks tied to governance.
The board must next determine whether to appoint an interim replacement or expand the search for a permanent director, actions that typically trigger additional SEC filings within four business days of election.
This filing is the latest board-level change for the clinical-stage biotechnology company, which has been advancing its pipeline of inflammatory bowel disease candidates. Spyre Therapeutics, ticker SYRE, originally went public through a SPAC merger in 2023 and has used subsequent 8-K filings to report executive and director transitions as it builds its leadership team post-merger.
The complete 8-K includes Item 9.01 exhibits, which typically contain any related press release or board resolution, though the primary record does not quote additional text beyond the standard Item 5.02 disclosure.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Related Stories
Japan TimesIsraeli Forces Cross Litani River, Seize Beaufort Castle in Lebanon
Israeli troops crossed the Litani River and seized the historic Beaufort castle near Nabatieh on Sunday. The move marks Israel's broadest ground incursion into Lebanon in 25 years.
rediff.comIran Demands Concrete Sanctions Relief Before Any Nuclear Deal With U.S.
Iran's parliament speaker stated that Tehran will not approve any agreement until it receives firm guarantees. The remarks come amid stalled talks and recent U.S. strikes on an Iranian port city.
azernews.azGermany Increases Defense Spending and Training After Russia Invades Ukraine
Germany has raised military recruitment and spending since Russia's 2022 invasion of Ukraine. The Bundeswehr reported a 23 percent rise in enlistments last year. The defense budget is projected to increase nearly 80 percent by 2029.